{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T23:01:26Z","timestamp":1780268486509,"version":"3.54.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82571880"],"award-info":[{"award-number":["82571880"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Guangxi Medical University Training Program for Distinguished Young Scholars"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04330-6","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:42:03Z","timestamp":1776332523000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive value of PD-L1 expression and dMMR\/pMMR status for immune checkpoint inhibitor combined with chemotherapy in advanced\/recurrent endometrial cancer: a meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Lifang","family":"Lan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuangyan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongwei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"8","key":"4330_CR1","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","volume":"26","author":"N Concin","year":"2025","unstructured":"Concin N, Matias-Guiu X, Cibula D, et al. ESGO\u2013ESTRO\u2013ESP Guidelines for the Management of Patients with Endometrial Carcinoma: Update 2025. Lancet Oncol. 2025;26(8):e423\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(25)00167-6.","journal-title":"Lancet Oncol"},{"issue":"3","key":"4330_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"10333","key":"4330_CR3","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00296-5","volume":"399","author":"EJ Crosbie","year":"2022","unstructured":"Crosbie EJ, Hooker AE, Kitchener HC, Prentice A. Endometrial cancer. Lancet. 2022;399(10333):1412\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(22)00296-5.","journal-title":"Lancet"},{"issue":"8","key":"4330_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.6004\/jnccn.2025.0038","volume":"23","author":"NR Abu-Rustum","year":"2025","unstructured":"Abu-Rustum NR, Campos SM, Amarnath S, et al. NCCN Guidelines\u00ae Insights: Uterine Neoplasms, Version 3.2025: Featured Updates to the NCCN Guidelines\u00ae. J Natl Compr Canc Netw. 2025;23(8):284\u201391. https:\/\/doi.org\/10.6004\/jnccn.2025.0038.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"4330_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-021-00301-z","volume":"9","author":"W Cao","year":"2021","unstructured":"Cao W, Ma X, Fischer JV, et al. Immunotherapy in endometrial cancer: rationale, practice and perspectives. Biomark Res. 2021;9(1):49. https:\/\/doi.org\/10.1186\/s40364-021-00301-z.","journal-title":"Biomark Res"},{"issue":"24","key":"4330_CR6","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","volume":"380","author":"D Matei","year":"2019","unstructured":"Matei D, Filiaci V, Randall ME, et al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med. 2019;380(24):2317\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1813181.","journal-title":"N Engl J Med"},{"key":"4330_CR7","doi-asserted-by":"publisher","first-page":"e080978","DOI":"10.1136\/bmj-2024-080978","volume":"388","author":"BR Corr","year":"2025","unstructured":"Corr BR, Swaby RJ, Quinn MA, et al. Advances in the management of endometrial cancer. BMJ. 2025;388:e080978. https:\/\/doi.org\/10.1136\/bmj-2024-080978.","journal-title":"BMJ"},{"key":"4330_CR8","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.3332\/ecancer.2025.1884","volume":"19","author":"M Carvalho Gouveia","year":"2025","unstructured":"Carvalho Gouveia M, Colombo Bonadio R, Lazar Neto F, et al. PD-1 or PD-L1 Inhibitors in Addition to First-Line Chemotherapy for Endometrial Cancer: An Extracted Individual Patient Data Meta-Analysis. Ecancermedicalscience. 2025;19:1884. https:\/\/doi.org\/10.3332\/ecancer.2025.1884.","journal-title":"Ecancermedicalscience"},{"key":"4330_CR9","doi-asserted-by":"publisher","unstructured":"Mirza MR, Lorusso D, Shen Q et al. Corrigendum to First-line treatments for advanced or recurrent endometrial cancer: Systemic literature review of clinical evidence [Crit Rev Oncol Hematol. 2025;206:104555]. Ann Oncol. 2025;S0923-7534(24)00056\u2009\u2013\u20095. https:\/\/doi.org\/10.1016\/j.annonc.2024.01.009.","DOI":"10.1016\/j.annonc.2024.01.009"},{"issue":"6","key":"4330_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Shivananda S, Kopetz S. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361\u201375. https:\/\/doi.org\/10.1038\/s41575-019-0126-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"4330_CR11","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.21873\/anticanres.17641","volume":"45","author":"JP Micha","year":"2025","unstructured":"Micha JP, Makarova O, Sessa C, et al. Immunotherapy and Chemotherapy for Advanced or Recurrent Endometrial Carcinoma. Anticancer Res. 2025;45(7):2711\u20137. https:\/\/doi.org\/10.21873\/anticanres.17641.","journal-title":"Anticancer Res"},{"issue":"1","key":"4330_CR12","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1186\/s12885-024-13058-z","volume":"24","author":"D Huang","year":"2024","unstructured":"Huang D, Zhang Y, Li Y, et al. Efficacy and safety of immune checkpoint inhibitors for advanced or recurrent endometrial cancer: a systematic review and network meta-analysis. BMC Cancer. 2024;24(1):1298. https:\/\/doi.org\/10.1186\/s12885-024-13058-z.","journal-title":"BMC Cancer"},{"issue":"5","key":"4330_CR13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"LA Diaz Jr","year":"2022","unstructured":"Diaz LA Jr, Shiu KK, Kim TW, et al. Pembrolizumab versus Chemotherapy for Microsatellite Instability-High or Mismatch Repair-Deficient Metastatic Colorectal Cancer (KEYNOTE-177): Final Analysis of a Randomized, Open-Label, Phase 3 Study. Lancet Oncol. 2022;23(5):659\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(22)00197-8.","journal-title":"Lancet Oncol"},{"issue":"11","key":"4330_CR14","doi-asserted-by":"publisher","first-page":"103967","DOI":"10.1016\/j.esmoop.2024.103967","volume":"9","author":"V Formica","year":"2024","unstructured":"Formica V, Falcone A, Aprile G, et al. PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials. ESMO Open. 2024;9(11):103967. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103967.","journal-title":"ESMO Open"},{"key":"4330_CR15","doi-asserted-by":"publisher","first-page":"1021859","DOI":"10.3389\/fonc.2022.1021859","volume":"12","author":"M Noori","year":"2022","unstructured":"Noori M, Rahmati M, Ghaffari SE, et al. Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for esophageal cancer treatment: A systematic review and meta-analysis. Front Oncol. 2022;12:1021859. https:\/\/doi.org\/10.3389\/fonc.2022.1021859.","journal-title":"Front Oncol"},{"issue":"19","key":"4330_CR16","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"N Engl J Med"},{"issue":"22","key":"4330_CR17","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.2018.80.4115","volume":"37","author":"EB Garon","year":"2019","unstructured":"Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019;37(22):2518\u201327. https:\/\/doi.org\/10.1200\/JCO.2018.80.4115.","journal-title":"J Clin Oncol"},{"issue":"22","key":"4330_CR18","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1158\/1078-0432.CCR-22-3915","volume":"29","author":"A Oaknin","year":"2023","unstructured":"Oaknin A, Pothuri B, Gilbert L, et al. Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study. Clin Cancer Res. 2023;29(22):4564\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3915.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4330_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/GCO.0000000000000996","volume":"35","author":"HC Karpel","year":"2023","unstructured":"Karpel HC, Slomovitz B, Coleman RL, Pothuri B. Treatment Options for Molecular Subtypes of Endometrial Cancer in 2023. Curr Opin Obstet Gynecol. 2023;35(3):270\u20139. https:\/\/doi.org\/10.1097\/GCO.0000000000000996.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"oct18 2","key":"4330_CR20","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, Gotzsche PC, et al. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials[J]. BMJ. 2011;343(oct18 2):d5928\u20135928.","journal-title":"BMJ"},{"issue":"3","key":"4330_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.23.02132","volume":"42","author":"SN Westin","year":"2024","unstructured":"Westin SN, Moore K, Chon HS, et al. DUO-E: A Randomized, Phase III Study of Durvalumab Plus Chemotherapy With or Without Tremelimumab in Patients With Advanced or Recurrent Endometrial Cancer. J Clin Oncol. 2024;42(3):283\u201399. https:\/\/doi.org\/10.1200\/JCO.23.02132.","journal-title":"J Clin Oncol"},{"key":"4330_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ygyno.2024.10.022","volume":"192","author":"MA Powell","year":"2025","unstructured":"Powell MA, Cibula D, O\u2019Malley DM, et al. RUBY: A Phase III Randomized Study of Dostarlimab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Endometrial Cancer. Gynecol Oncol. 2025;192:40\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2024.10.022.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"4330_CR23","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/s41591-025-03566-1","volume":"31","author":"RN Eskander","year":"2025","unstructured":"Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nat Med. 2025;31(5):1539\u201346. https:\/\/doi.org\/10.1038\/s41591-025-03566-1.","journal-title":"Nat Med"},{"issue":"9","key":"4330_CR24","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","volume":"25","author":"N Colombo","year":"2024","unstructured":"Colombo N, Biagioli E, Harano K, et al. AtTEnd: A Phase III Randomized Study of Avelumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Endometrial Cancer. Lancet Oncol. 2024;25(9):1135\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(24)00334-6.","journal-title":"Lancet Oncol"},{"issue":"3","key":"4330_CR25","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S1470-2045(23)00016-5","volume":"24","author":"S Pignata","year":"2023","unstructured":"Pignata S, Scambia G, Schettino C, et al. MITO END-3: A Phase II Randomized Study of Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Advanced Endometrial Cancer. Lancet Oncol. 2023;24(3):286\u201396. https:\/\/doi.org\/10.1016\/S1470-2045(23)00016-5.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4330_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ccell.2020.11.004","volume":"39","author":"J Guan","year":"2021","unstructured":"Guan J, Lu C, Jin Q, et al. MLH1 Deficiency-Triggered DNA Hyper-Excision by Exonuclease 1 Activates the cGAS-STING Pathway. Cancer Cell. 2021;39(1):109\u2013e1215. https:\/\/doi.org\/10.1016\/j.ccell.2020.11.004.","journal-title":"Cancer Cell"},{"issue":"1","key":"4330_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ccell.2020.12.016","volume":"39","author":"M Gerlinger","year":"2021","unstructured":"Gerlinger M. Immunotherapy Sensitivity of Mismatch Repair-Deficient Cancer: Mutation Load Is Not Enough. Cancer Cell. 2021;39(1):16\u20138. https:\/\/doi.org\/10.1016\/j.ccell.2020.12.016.","journal-title":"Cancer Cell"},{"issue":"12","key":"4330_CR28","doi-asserted-by":"publisher","first-page":"e20250265","DOI":"10.1084\/jem.20250265","volume":"222","author":"Y Xu","year":"2025","unstructured":"Xu Y, Zhou Z, Chen W, et al. Tumors with Microsatellite Instability Upregulate TREX1 to Escape Antitumor Immunity. J Exp Med. 2025;222(12):e20250265. https:\/\/doi.org\/10.1084\/jem.20250265.","journal-title":"J Exp Med"},{"issue":"2","key":"4330_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/JCO.21.01015","volume":"40","author":"HJ Lenz","year":"2022","unstructured":"Lenz HJ, Yoshino T, Van Cutsem E, et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. 2022;40(2):161\u201370. https:\/\/doi.org\/10.1200\/JCO.21.01015.","journal-title":"J Clin Oncol"},{"issue":"21","key":"4330_CR30","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","volume":"390","author":"M Chalabi","year":"2024","unstructured":"Chalabi M, Verschoor YL, Tan PB, et al. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2024;390(21):1949\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2400634.","journal-title":"N Engl J Med"},{"issue":"6","key":"4330_CR31","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","volume":"20","author":"C Eng","year":"2019","unstructured":"Eng C, Kim TW, Bendell J, et al. Atezolizumab with or without Cobimetinib versus Regorafenib in Previously Treated Metastatic Colorectal Cancer (IMblaze370): A Multicentre, Open-Label, Phase 3, Randomized, Controlled Trial. Lancet Oncol. 2019;20(6):849\u201361. https:\/\/doi.org\/10.1016\/S1470-2045(19)30027-0.","journal-title":"Lancet Oncol"},{"issue":"4","key":"4330_CR32","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41591-024-02813-1","volume":"30","author":"F Wang","year":"2024","unstructured":"Wang F, Jin Y, Wang M, et al. Combined Anti-PD-1, HDAC Inhibitor and Anti-VEGF for MSS\/pMMR Colorectal Cancer: A Randomized Phase 2 Trial. Nat Med. 2024;30(4):1035\u201343. https:\/\/doi.org\/10.1038\/s41591-024-02813-1.","journal-title":"Nat Med"},{"issue":"14","key":"4330_CR33","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.7150\/ijbs.64077","volume":"17","author":"A Fan","year":"2021","unstructured":"Fan A, Wang B, Wang X, et al. Immunotherapy in Colorectal Cancer: Current Achievements and Future Perspective. Int J Biol Sci. 2021;17(14):3837\u201349. https:\/\/doi.org\/10.7150\/ijbs.64077.","journal-title":"Int J Biol Sci"},{"key":"4330_CR34","doi-asserted-by":"publisher","first-page":"103421","DOI":"10.1016\/j.eclinm.2025.103421","volume":"87","author":"L Zhao","year":"2025","unstructured":"Zhao L, Liu H, Yu J, et al. Efficacy and Safety of Neoadjuvant Toripalimab plus Chemotherapy in Localized Deficient Mismatch Repair\/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma (NICE): A Multicentre, Single-Arm, Exploratory Phase 2 Study. EClinicalMedicine. 2025;87:103421. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103421.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"4330_CR35","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","volume":"7","author":"J Chao","year":"2021","unstructured":"Chao J, Fuchs CS, Shitara K, et al. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncol. 2021;7(6):895\u2013902. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0275.","journal-title":"JAMA Oncol"},{"issue":"7","key":"4330_CR36","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3760\/cma.j.cn441530-20240526-00188","volume":"27","author":"YJ Li","year":"2024","unstructured":"Li YJ, Yuan P, Zhai JN, et al. Efficacy and Safety of Preoperative Programmed Death Protein-1 Inhibitor Combined with Chemotherapy in Immunotherapy-Sensitive Patients with Locally Advanced Gastric Cancer or Adenocarcinoma of the Esophagogastric Junction. Zhonghua Wei Chang Wai Ke Za Zhi. 2024;27(7):684\u201393. https:\/\/doi.org\/10.3760\/cma.j.cn441530-20240526-00188.","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"issue":"4","key":"4330_CR37","doi-asserted-by":"publisher","first-page":"434","DOI":"10.6004\/jnccn.2025.0022","volume":"23","author":"JA Ajani","year":"2025","unstructured":"Ajani JA, Bekaii-Saab TS, Boshoff C, et al. NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers, Version 4.2025. J Natl Compr Canc Netw. 2025;23(4):434\u201364. https:\/\/doi.org\/10.6004\/jnccn.2025.0022.","journal-title":"J Natl Compr Canc Netw"},{"key":"4330_CR38","doi-asserted-by":"publisher","first-page":"102890","DOI":"10.1016\/j.ctrv.2025.102890","volume":"134","author":"C Fouchardi\u00e8re","year":"2025","unstructured":"Fouchardi\u00e8re C, Ducreux M, Labianca R, et al. How do I treat dMMR\/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force. Cancer Treat Rev. 2025;134:102890. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102890.","journal-title":"Cancer Treat Rev"},{"issue":"23","key":"4330_CR39","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","volume":"392","author":"A Cercek","year":"2025","unstructured":"Cercek A, Saikali S, Cohen OJ, et al. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med. 2025;392(23):2297\u2013308. https:\/\/doi.org\/10.1056\/NEJMoa2404512.","journal-title":"N Engl J Med"},{"key":"4330_CR40","volume-title":"CSCO Clinical Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer (2025 Edition)","author":"Chinese Society of Clinical Oncology (CSCO)","year":"2025","unstructured":"Chinese Society of Clinical Oncology (CSCO). CSCO Clinical Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer (2025 Edition). Beijing: People\u2019s Medical Publishing House; 2025."},{"key":"4330_CR41","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (Version 8.2025)","author":"National Comprehensive Cancer Network (NCCN)","year":"2025","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (Version 8.2025). Plymouth Meeting: NCCN; 2025."},{"issue":"1","key":"4330_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"F Wang","year":"2023","unstructured":"Wang F, Zhang X, Tang L, et al. The Chinese Society of Clinical Oncology (CSCO): Clinical Guidelines for the Diagnosis and Treatment of Gastric Cancer, 2023. Cancer Commun. 2023;44(1):127\u201372. https:\/\/doi.org\/10.1002\/cac2.12516.","journal-title":"Cancer Commun"},{"issue":"2","key":"4330_CR43","doi-asserted-by":"publisher","first-page":"104134","DOI":"10.1016\/j.esmoop.2025.104134","volume":"10","author":"T Leong","year":"2025","unstructured":"Leong T, Cervantes A, Dreyer Z, et al. ESMO Clinical Practice Guideline Interim Update on the Treatment of Locally Advanced Oesophageal and Oesophagogastric Junction Adenocarcinoma and Metastatic Squamous-Cell Carcinoma. ESMO Open. 2025;10(2):104134. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104134.","journal-title":"ESMO Open"},{"key":"4330_CR44","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (Version 3.2025)","author":"National Comprehensive Cancer Network (NCCN)","year":"2025","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (Version 3.2025). Plymouth Meeting: NCCN; 2025."}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04330-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04330-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04330-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T22:37:16Z","timestamp":1780267036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04330-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4330"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04330-6","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"233"}}